Best Practices in the CDMO Selection Process

Publications
Category:
Published on:
September 8, 2022
We are pleased to bring you a new series on “Best Practices in the CDMO Selection Process”

Pharmaceutical development companies of all sizes frequently outsource their Active Pharmaceutical Ingredient (API) manufacturing to CDMOs for various reasons, including: a) limited internal know-how and capacity to manufacture API according to Good Manufacturing Practice (GMP) or b) to reduce costs and timelines.

The CDMO series provides sound advice to agile biotech companies in identifying and selecting the right Contract Development and Manufacturing Organization (CDMO) for advancing the development of their product(s), in conjunction with successfully managing a chosen CDMO to meet the company’s expectations.

In these articles, we will explore the common reasons why a company might consider engaging a CDMO. We will focus on how to the evaluate CDMOs, detail the best practices for working with a CDMO to ensure the success of your product development, and more.

Best Practices in the CDMO Selection Process

CDMO
Why—and When—to Use a CDMO
In this 1st article of the series, we explore three common reasons why a company might consider engaging a CDMO.
CDMO
Determine Your Priorities to Finding the Right CDMO
In this 2nd article of the series, we detail the best practices for working with a CDMO to ensure the success of your product development.
CDMO
What to Look for in a CDMO
In this 3rd article of the series, we focus on the evaluation of a few identified CDMOs. There are several factors to consider and while some may be subjective to your company’s needs and culture, most should be quantifiable and tracked in a spreadsheet that lets you compare potential CDMOs in a like-for-like way.
CDMO
Critical Quality Attributes for Drug Products
In this 4th article in the series, we explore the importance of Critical Quality Attributes (CQAs) in the drug development lifecycle and why it is vital that your selected CDMO is capable of addressing them.
CDMO
How To Choose the Right Analytical Methods
5th article of the series
Coming soon

Related news

Publications September 14, 2022
Critical Quality Attributes for Drug Products
In this article, we will explore the importance of Critical Quality Attributes (CQAs) in the drug development lifecycle and why it is vital that your selected CDMO is capable of addressing them.
Biotech CDMO Drug Development
Publications September 8, 2022
Best Practices in the CDMO Selection Process
The CDMO series provides sound advice to agile biotech companies in identifying and selecting the right Contract Development and Manufacturing Organization (CDMO) for advancing the(...)
CDMO
Publications September 8, 2022
What to Look for in a CDMO
In this article we will focus on the evaluation of a few identified CDMOs. There are several factors to consider and while some may be subjective to your company’s needs and culture,(...)
Biotech CDMO Contract Development and Manufacturing
Publications September 1, 2022
Determine Your Priorities to Finding the Right CDMO
In this article, we will detail the best practices for working with a CDMO to ensure the success of your product development. After having identified the need for engaging a CDMO, the(...)
Biotech CDMO Contract Development and Manufacturing
Publications August 25, 2022
Why—and When—to Use a CDMO
Pharmaceutical development companies of all sizes frequently outsource their Active Pharmaceutical Ingredient (API) manufacturing to CDMOs for various reasons. In this article, we explore(...)
CDMO Pharma Research and Development
Publications May 27, 2022
The Impact of Chip Shortage on the MedTech Sector and RAS Players
Discover the three factors driving the chip shortage, the impact, and what’s next for Robotic and MedTech industry at large.
CDMO MedTech Robotcs
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.